Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: Results from the Vienna cancer and Thrombosis Study (CATS)

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 200-206

  Posch, Florian ^a   Thaler, Johannes ^a   Zlabinger, Gerhard Johann ^b   Königsbrügge, Oliver ^a   Koder, Silvia ^a   Zielinski, Christoph ^a   Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; PADGEM PROTEIN; THROMBIN; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRIA; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; INCIDENCE; KIDNEY CANCER; LIMIT OF DETECTION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOMA; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN LOCALIZATION; REMISSION; RISK ASSESSMENT; SEX DIFFERENCE; TUMOR LOCALIZATION; VENOUS THROMBOEMBOLISM; BLOOD; CANCER GRADING; CANCER STAGING; COMPLICATION; MORTALITY; NEOPLASMS; PROGNOSIS; RISK;

AGED; BIOMARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; RISK; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOEMBOLISM;

EID: 84954496670     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3358     Document Type: Article

References (29)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46.
3. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189-204.
4. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7.
5. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost 2012;108:1042-8.
6. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377-82.
7. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013;122:2011-8.
8. Ferrara N, Gerber HP, Le Couter J. The biology of VEGFand its receptors. Nat Med 2003;9:669-76.
9. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397-405.
10. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999;93:3811-23.
11. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:531-7.
12. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br JCancer 1997;76:238-43.
13. Hu P, Liu W, Wang L, Yang M, Du J. High circulating VEGF level predicts poor overall survival in lung cancer. J Cancer Res Clin Oncol 2013; 139:1157-67.
14. Jurgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 2013;108:1316-23.
15. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005;23:193-200.
16. Dogan M, Demirkazik A. Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. Support Cancer Ther 2005;3: 28-34.
17. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.
18. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012;97:1158-64.
19. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011;29:2099-103.
20. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. Ddimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124-9.
21. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-8.
22. Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009;29:2176-81.
23. Coviello V BM. Cumulative incidence estimation in the presence of competing risks. Stata J 2004;4:103-12.
24. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008;26: 4027-34.
25. Huck V, Schneider MF, Gorzelanny C, Schneider SW. The various states of von Willebrand factor and their function in physiology and pathophysiology. Thromb Haemost 2014;111:598-609.
26. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012;52:510-6.
27. Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol 2014;21:423-9.
28. Milanovic N, Matkovic S, Ristic D, Jelic S, Petrovic M. Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON 2012;17:497-501.
29. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898-905.